Mexican product released in U.S. may prevent erectile dysfunction
SAN FRANCISCO Hispanic men between the ages of 20 and 50 are two and a half times as likely as men of other races and ethnicities to develop erectile dysfunction, according to a study published in the Archives of Internal Medicine in 2005.
A product on the market in Mexico since 2004 and recently introduced in the United States might address the problem. CRB Ventures said the product, The Sensual Tea, has a rate of effectiveness of 87.3 percent in treating erectile dysfunction and premature ejaculation and has no side effects.
“It is possible to prevent sexual problems from ever occurring,” CRB Ventures president Christian Beasley said in a statement. “The Sensual Tea overcomes low libido and sexual fatigue and enhances the pleasure and intensity of sex.”
Valeant pays $285 million for derm drug maker
ALISO VIEJO, Calif. Valeant Pharmaceuticals has agreed to buy Dow Pharmaceutical Sciences—which makes drugs to treat acne and other skin conditions, primarily for other pharmaceutical companies—for $285 million, according to several reports.
The deal, set to close in the next few weeks, considerably expands Valeant’s presence in the dermatological space.
The privately held Dow Pharmaceutical Sciences—no connection to Dow Chemical—recently received FDA approval for a new prescription topical acne medication, Acanya, which is expected to hit the market early next year and is projected to reach sales of $70 million.
Valeant also will inherit the rest of Dow’s considerable new product development pipeline, including several other drugs for treating rosacea, fungal infections and warts.
The Dow acquisition comes close on the heels of Valeant’s November purchase of Australian skin care remedy maker DermaTech Pty Ltd., for a little more than $12 million. DermaTech makes drugs for treating acne, psoriasis, warts, head lice and nits, both prescription and OTC.
Analysts are regarding the recent moves as a bit of a “turnaround story,” for the northern California-based company formerly known as ICN Pharmaceuticals, which last year reemerged as Valeant Pharmaceuticals following a considerable restructuring.
OTC sleep aids get boost from boomers
NEW YORK The market for OTC sleep aids is thriving, thanks in large part to baby boomers, according to a recent research report.
A new report by market research publisher Packaged Facts estimates that the total OTC market for sleep aids alone reached $604 million in 2008, an increase of 9 percent compared with $533 million in 2007. The increase was on par with the 8 percent compound annual growth rate that OTC sleep aids experienced between 2004 and 2008.
Both short-term and long-term success of the market is tied to aging baby boomers, a high-income populace less likely to feel the economic crunch as strongly as consumers with more moderate levels of income, the report states.
Furthermore, women of the baby boomer generation tend to face unique sleep challenges. As women age, more than half entering their menopausal transition years can expect to experience various primary sleep disorders, including sleep apnea, snoring, restless legs syndrome or insomnia.
“Sleep disorders are under-diagnosed in menopausal women, and many experts now recommend special consideration when diagnosing and treating their sleep problems,” stated Tatjana Meerman, publisher of Packaged Facts.